Periodontal health in a cohort of subjects with type 1 diabetes mellitus
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Dental Research"
DOI: 10.1002/cre2.178
Abstract: To evaluate periodontal health and oral health behaviors in a cohort of subjects with type 1 diabetes (T1D), 50 persons with T1D (30 males and 20 females; mean age: 35.2 years) were recruited from the… read more here.
Keywords: periodontal health; health cohort; type diabetes; health ... See more keywords
Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cell Communication and Signaling"
DOI: 10.1007/s12079-019-00536-4
Abstract: Background Wnt1-inducible signaling pathway protein 1, or cellular communication network factor 4 (CCN4), a member of CCN family of secreted, extracellular matrix associated signaling proteins, recently was validated as a novel adipose tissue derived cytokine.… read more here.
Keywords: wnt1 inducible; ccn4; signaling pathway; type diabetes ... See more keywords
Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01094-y
Abstract: Cotadutide is a balanced dual glucagon-like peptide-1/glucagon receptor agonist under development for the treatment of nonalcoholic steatohepatitis and chronic kidney disease with type 2 diabetes. The objectives of the analysis were to characterize the population… read more here.
Keywords: population pharmacokinetics; type diabetes; pharmacokinetics cotadutide; cotadutide ... See more keywords
A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2017.01.019
Abstract: AIMS The glucagon receptor antagonist PF-06291874 has demonstrated robust glucose reductions in subjects with type 2 diabetes mellitus (T2DM) on background metformin. This study assessed the pharmacokinetics, pharmacodynamics, safety, and tolerability of PF-06291874 administered as… read more here.
Keywords: receptor antagonist; monotherapy; safety; glucagon receptor ... See more keywords
The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2018.1509304
Abstract: Abstract Objective: The objective of this study was to compare the efficacy and safety of pregabalin for painful diabetic peripheral neuropathy (pDPN) in subjects with type 1 (T1DM) or 2 diabetes mellitus (T2DM). Methods: Pooled… read more here.
Keywords: pregabalin; peripheral neuropathy; t1dm t2dm; diabetic peripheral ... See more keywords
Glucose‐targeted therapy for subjects with type 2 diabetes mellitus: primum non nocere
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Clinical Investigation"
DOI: 10.1111/eci.12791
Abstract: Type 2 Diabetes (T2DM) is a complex disease that is not limited to hyperglycemia. Anti-diabetic treatments aimed at preventing late onset complications and avoiding both hypo- and hyperglycemic events. Unfortunately, recently discovered anti-diabetic drugs only… read more here.
Keywords: therapy subjects; targeted therapy; type diabetes; diabetes mellitus ... See more keywords
Hypoglycemia does not affect the progression of preclinical atherosclerosis in subjects with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0212871
Abstract: Introduction Intensive treatment aimed at achieving optimal metabolic control to prevent the development of chronic diabetic complications is often associated with an increased rate of hypoglycemic events. Hypoglycemia is believed to be responsible for acute… read more here.
Keywords: hypoglycemia affect; hypoglycemia; preclinical atherosclerosis; type diabetes ... See more keywords
Altered microvasculature in pancreatic islets from subjects with type 1 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0276942
Abstract: Aims The transcriptome of different dissociated pancreatic islet cells has been described in enzymatically isolated islets in both health and disease. However, the isolation, culturing, and dissociation procedures likely affect the transcriptome profiles, distorting the… read more here.
Keywords: islets subjects; subjects type; type diabetes; altered microvasculature ... See more keywords
2233-PUB: Clinical Features and Biomarkers of Nonalbuminuric and Albuminuric Patterns of Chronic Kidney Disease in Subjects with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-2233-pub
Abstract: The Aim: to define the phenotypes of non-albuminuric and albuminuric chronic kidney disease (NA-CKD and A-CKD) in subjects with type 2 diabetes (T2D). Methods: One hundred and eighty four T2D patients were included in the… read more here.
Keywords: chronic kidney; subjects type; type diabetes; disease ... See more keywords
Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.871660
Abstract: There are many tests for evaluating endogenous insulin secretory capacity. However, there are only a limited number of studies that have examined in detail in clinical practice which method most accurately reflects the ability to… read more here.
Keywords: withdrawal; endogenous insulin; test; subjects type ... See more keywords